Stay updated on SAGE-217 in Parkinson's Disease: Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 in Parkinson's Disease: Clinical Trial page.

Latest updates to the SAGE-217 in Parkinson's Disease: Clinical Trial page
- Check4 days agoChange DetectedThe completed Phase 2 SAGE-217 study for people with Parkinson’s disease is displayed, including its design, eligibility criteria, locations, and reported outcome measures. The record also includes Biogen’s sponsor information and links to study documents and participant-data sharing details.SummaryDifference100%

- Check11 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice about terminology changes under Executive Order 14434 appears above the 403 error page. The site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden response instead of study details.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header, and many study-related links and documents have been removed, blocking access to the study record.SummaryDifference26%

- Check60 days agoChange DetectedRevision label on the page was updated from v3.6.6 to v3.7.0, indicating a metadata/template update rather than changes to the study information or eligibility details.SummaryDifference0.0%

Stay in the know with updates to SAGE-217 in Parkinson's Disease: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 in Parkinson's Disease: Clinical Trial page.